sana biotechnology news

type 1 diabetes, Sana and Beta cell

Sana’s cell therapy may be ‘transformative cure’ for type 1 diabetes: analysts

Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with type 1 diabetes, sending the company’s share price up by about 200%. | Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with type 1 diabetes,

Business Insider · 1d

Sana Biotechnology’s Hypoimmune Platform: A Transformative Breakthrough in Type 1 Diabetes Treatment and Beyond

Samantha Semenkow, an analyst from Citi, maintained the Buy rating on Sana Biotechnology (SANA – Research Report). The associated price target

YAHOO!Finance · 1d

Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results Demonstrate HIP-Engineered Primary Pancreatic Islet Cells Avoid Immune Detection,

Hosted on MSN21h

Sana Biotech Stock Triples After Type 1 Diabetes Trial Wows Analysts: Retail Erupts In Excitement

Sana Biotechnology Inc.'s stock soared over 200% on Wednesday, on track to mark its best day on record, amid trading volumes ...

19h

Sana Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 43 rd Annual J.P ...

Sana Biotechnology Stock Surges Over 200% On Wednesday - Here's Why

Sana Biotechnology's first-in-human study shows UP421 pancreatic islet cells surviving and functioning in type 1 diabetes ...

Hosted on MSN23h

TD Cowen Upgrades Sana Biotechnology (SANA)

Fintel reports that on January 8, 2025, TD Cowen upgraded their outlook for Sana Biotechnology (NasdaqGS:SANA) from Hold to ...

Sana Biotechnology: Stock Price Rise Deserved Post Diabetes Cell Therapy Success

Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...

bovnews1d

Sana Biotechnology’s (SANA) Revolutionary Breakthrough Sends Stock Soaring

Sana Biotechnology’s innovative approach to treating type 1 diabetes centers around its HIP-modified pancreatic islet cell transplant. In the context of type 1 diabetes, the body’s immune system ...

BioPharma Dive1d

Tenvie raises $200M for brain drug R&D; Sana spikes on single patient’s results

The Arch-backed startup begins life with several assets acquired from Denali Therapeutics. Elsewhere, Jasper got a negative ...

Sana Biotechnology Shares Spike Following Successful Transplantation

Shares of Sana Biotechnology surged after the company released what it assessed as positive data from a study of its in-development treatment for type 1 diabetes. The stock more than tripled, up 265% ...

bovnews20h

Sana Biotechnology Inc (SANA) Stock: Unveiling Its Hidden Strengths

Sana Biotechnology Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -68.45%. The profit margin, also known as the revenue ratio or gross profit ratio ...

21hon MSN

Sana Biotech extends rally as Morgan Stanley cites platform's potential

Sana Biotechnology (SANA) stock soared after Phase 1 data for its cell therapy which, according to Morgan Stanley, has ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results